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Abstract
Anemia, usually due to iron deficiency, is highly preva-
lent among patients with colorectal cancer. Inflam-
matory cytokines lead to iron restricted erythropoiesis 
further decreasing iron availability and impairing iron 
utilization. Preoperative anemia predicts for decreased 
survival. Allogeneic blood transfusion is widely used to 
correct anemia and is associated with poorer surgical 
outcomes, increased post-operative nosocomial infec-
tions, longer hospital stays, increased rates of cancer 
recurrence and perioperative venous thromboembo-
lism. Infections are more likely to occur in those with 
low preoperative serum ferritin level compared to those 
with normal levels. A multidisciplinary, multimodal, in-
dividualized strategy, collectively termed Patient Blood 
Management, minimizes or eliminates allogeneic blood 
transfusion. This includes restrictive transfusion policy, 
thromboprophylaxis and anemia management to im-
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prove outcomes. Normalization of preoperative hemo-
globin levels is a World Health Organization recom-
mendation. Iron repletion should be routinely ordered 
when indicated. Oral iron is poorly tolerated with low 
adherence based on published evidence. Intravenous 
iron is safe and effective but is frequently avoided due 
to misinformation and misinterpretation concerning 
the incidence and clinical nature of minor infusion re-
actions. Serious adverse events with intravenous iron 
are extremely rare. Newer formulations allow complete 
replacement dosing in 15-60 min markedly facilitating 
care. Erythropoiesis stimulating agents may improve 
response rates. A multidisciplinary, multimodal, indi-
vidualized strategy, collectively termed Patient Blood 
Management used to minimize or eliminate allogeneic 
blood transfusion is indicated to improve outcomes.
© 2014 Baishideng Publishing Group Co., Limited. All rights 
reserved.
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Core tip: Anemia, usually due to iron deficiency, is high-
ly prevalent among patients with colorectal cancer. Both 
anemia and allogeneic blood transfusion are associated 
with poorer outcomes. Anemia management, within a 
multidisciplinary, multimodal, individualized strategy to 
minimize or eliminate allogeneic blood transfusion, is 
indicated to improve outcomes. Intravenous iron is safe 
and effective but underused, despite the extremely low 
risk of causing serious adverse events. Newer intra-
venous iron formulations allow complete replacement 
dosing in 15-60 min markedly facilitating care. Erythro-
poiesis stimulating agents may improve response rates. 
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PREVALENCE OF ANEMIA AND IRON 
DEFICIENCY 
Anemia is one of  the most frequent extraintestinal mani-
festations of  colorectal cancer (CRC), and may be pres-
ent in 30%-75% of  patients, predicated on the level of  
hemoglobin (Hb) used to define anemia and tumor local-
ization and stage[1-7]. A study on 358 patients with CRC 
reported a 25% prevalence of  moderate to severe anemia 
(Hb < 10 g/dL). The multivariate analysis revealed that 
age, tumor site (right colon), and tumor size (large size), 
but not clinical stage or histological type, were significant 
contributing factors[2]. These results were corroborated 
by a study of  1189 Norwegian patients[7]. Lastly, a recent 
study showed that iron deficiency (ID) in CRC was as-
sociated with poor performance and more advanced dis-
ease[8].
CONSEQUENCES OF ANEMIA
Preoperative anemia is the major predictive factor for 
allogeneic blood transfusion (ABT) in surgeries with 
moderate to high perioperative blood loss, which is caus-
ative in postoperative anemia and aggravates pre-existing 
anemia[9]. In CRC resection, a hematocrit of  less than 
30% has been shown to be an independent risk factor for 
perioperative ABT[6,7,10,11]. Even mild-to-moderate preop-
erative anemia has been linked to increased postoperative 
morbidity and length of  hospital stay as well as decreased 
disease-free survival after resection[12-14]. This is supported 
by a recent publication in which preoperative anemia 
significantly worsened overall survival (P = 0.040) in the 
univariate analysis[15]. However, in the multivariate analy-
sis the difference did not approach statistical significance.
Both preoperative anemia and ID without anemia 
increase the rate of  postoperative nosocomial infection. 
Following abdominal surgery, infections were significantly 
more likely with low preoperative serum ferritins com-
pared with normal levels. The data were especially poi-
gnant in that confounders including Hb level were taken 
into account in the analysis[16]. Zago et al[17] evaluated the 
relationship of  vitamin and mineral levels to wound com-
plications in 100 abdominal surgical procedures, and not-
ed low plasma retinol (a marker of  low vitamin A intake) 
and high erythrocyte protoporphyrin (an early marker of  
ID) to be surrogates of  increased complications. Further 
evaluation of  the benefits of  these measurements as a 
standard of  care appears warranted.
PATHOPHYSIOLOGY OF ANEMIA
In CRC, preoperative anemia can be attributed to chronic 
hemorrhage, neoadjuvant chemotherapy or radiotherapy, 
and nutritional deficiencies. These may be exacerbated by 
activation of  the immune system with release of  inflam-
matory cytokines such as tumor necrosis factor alpha 
(TNF-α), interferon gamma (IFN-γ), and interleukins 
(IL)-1, -6, -8 and -10[18-20]. These inflammatory mediators 
cause anemia via a variety of  pathophysiological mecha-
nisms (Figure 1): (1) decreased red cell half-life due to 
dyserythropoiesis with red cell damage and increased 
erythrophagocytosis (TNF-α); (2) inadequate EPO re-
sponse for the severity of  anemia; (3) impaired respon-
siveness of  erythroid cells to EPO (IFN-γ, IL-1, and 
TNF-α); (4) inhibited proliferation and differentiation of  
erythroid cells (IFN-γ, IL-1, TNF-α, and α-1-antitrypsin); 
and (5) pathologic iron homeostasis due to increased di-
valent metal transport 1 (IFN-γ) and transferrin receptor 
expression (IL-10) in macrophages, reduced ferroportin 1 
expression (IFN-γ and IL-6-induced high hepcidin levels) 
in enterocytes and macrophages, and increased ferritin 
synthesis (TNF-α, IL-1, IL-6, IL-10).
Transferrin-bound iron is the primary iron source 
for erythropoiesis, entering the erythroblast by a process 
involving transferrin receptor-mediated endocytosis. This 
iron may be obtained by absorption of  dietary iron and/
or mobilization of  iron stores at macrophages and liver. 
Dietary non-hem iron primarily exists in an oxidised (Fe3+) 
form which is reduced to the Fe2+ form by a ferrireduc-
tase enzyme, before being transported across the intes-
tinal epithelium by a carrier protein called divalent metal 
transporter 1. Dietary heme iron enters the enterocyte by 
heme carrier protein, is metabolised by heme oxygenase 
to release Fe2+, which enters a common pathway with di-
etary non-hem iron before being exported by ferroportin 
1 across the basolateral membrane of  the enterocyte (ab-
sorbed iron). Iron export from the stores at macrophages 
and hepatocytes is also accomplished primarily by ferro-
portin 1. Iron is then oxidized, released into the circula-
tion, bound to transferrin and transported to sites of  use 
(Figure 2)[19,20].
The amount of  iron required for daily renewal of  red 
blood cells (20-30 mg) is provided mostly by senescent 
erythrocyte iron recycling at macrophages. Therefore, as 
daily absorption (1-2 mg) just balances daily loss, internal 
turnover of  iron is essential to meet the bone marrow 
requirements for erythropoiesis. 
Hepcidin, a 25-amino acid peptide produced mainly 
by hepatocytes in response IL-6 levels, plays a major 
role in dysregulation of  iron homeostasis during inflam-
mation. Once synthesised, hepcidin is secreted into the 
bloodstream and interacts with ferroportin 1 (the only 
known iron exporting protein) at enterocyte basolateral 
membrane, hepatocytes and macrophages (Figure 2). The 
binding of  hepcidin to ferroportin 1 causes internalization 
and lysosomal degradation of  the carrier protein. Thus, 
hepcidin regulates the rate of  iron absorption by villous 
enterocytes and the rate of  iron recirculation from mac-
rophages and hepatocytes, resulting in hypoferremia. In 
addition, inflammatory mediators increased divalent metal 
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transporter 1 (IFN-γ), transferrin receptor expression 
(IL-10) and ferritin synthesis (TNF-α, IL-1, IL-6, IL-10) 
in macrophages leading to increased iron storage[18-20]. 
Hypoferremia and increased reticuloendothelial iron 
result in decreased iron availability referred to as iron re-
stricted erythropoiesis or functional iron deficiency (FID); 
formerly referred to as anemia of  chronic disease. This is 
characterized by low serum iron and decreased transferrin 
saturation, in the face of  adequate body iron stores de-
fined by the presence of  stainable iron in the bone mar-
row and/or a serum ferritin value within or above normal 
limits. Finally, when persisting decreased iron absorption 
and/or chronic blood loss are present, FID may evolve 
to absolute iron deficiency (FID + ID). While hepcidin 
affects iron trafficking in FID and FID + ID, individuals 
suffering from FID + ID have significantly lower hepci-
din levels than those with FID without ID[21]. Individuals 
with both, in contrast to FID alone, absorb some dietary 
iron from the gut and mobilize some iron from macro-
phages. Thus, hepcidin levels may be useful in differenti-
ating between FID and FID + ID and in selecting appro-
priate therapy for these patients[21]. This is supported by a 
recent presentation by Steensma et al[22] who noted a 92% 
response rate to intravenous (iv) iron in chemotherapy 
induced anemia patients with low pretreatment hepci-
din levels. Hepcidin levels have been also shown useful 
in predicting non-responsiveness to oral iron therapy in 
patients with IDA[23]. Ward et al[24], in a cohort of  56 CRC 
patients, measured hepcidin in urine and determined hep-
cidin mRNA expression and hepcidin cellular localization 
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Figure 1  Pathophysiological mechanisms of anemia of inflammation in colorectal cancer. 1: Hepcidin release by colorectal cancer cells (CRC); 2,3: Decreased 
release of iron via ferroportin: leading to decreased transferrin-bound iron; 4: Decreased iron availability; 5: Reduced erythrocyte production; 6: Activation of immune 
system by CRC; 7: Release of immune and inflammatory cytokines; 8: Interleukin-6 (IL-6) induced hepcidin release; 9: Decreased erythropoietin (EPO) production; 

































Figure 2  A simplified scheme of main pathways of iron metabolism. 1: Ferrireductase; 2: Divalent metal transporter (DMT1); 3: Heme protein carrier 1; 4: Fer-
roportin; 5: Hephastin/ceruloplasmin; 6: Transferrin receptor-1 (TfR1); 7: Several mechanisms; IL-6: Interleukin 6; RBC: Red blood cell.
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Table 1  Main laboratory tests for the assessment of iron depletion
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estimate of  body iron stores (1 ng/mL of  ferritin = 8 mg 
of  stored iron)[34]. ID is defined as a ferritin level < 30 
ng/mL regardless patient’s inflammatory status. 
In the presence of  inflammation, TSAT < 20% and 
ferritin 30-100 ng/mL suggest absolute ID, whereas FID 
is generally defined by TSAT < 20% and ferritin ≥ 100 
ng/mL[30,32,33,35] (Figure 3). However, though ferritin val-
ues > 100 ng/mL argue against concurrent absolute ID 
in the setting of  inflammation, this test is imperfect due 
to its acute phase reactivity. Other tests can be utilized to 
evaluate for a component of  ID, which if  present sug-
gests a benefit toward iron supplementation. These tests 
include measurement of  the ratio of  the sTfR to log fer-
ritin and percent circulating hypochromic erythrocytes 
(increased in IDA and FID + ID), and the reticulocyte 
Hb content (low with IDA and FID + ID) (Table 1). 
Where available, hepcidin will help the diagnostic evalua-
tion in this regard; if  suppressed, a component of  abso-
lute ID is implied. IDA should be considered if  anemia 
with a TSAT < 20% and/or ferritin 30 ng/mL, with or 
without inflammation (Figure 3). Low MCV (< 80 fL) 
is a reliable and routinely part of  the automated CBC, 
but is a late indicator. In addition, IDA without microcy-
tosis may occur early in iron deficiency anemia prior to 
the development of  iron deficient erythropoiesis, when 
there is coexistinmg vitamin B12 or folate deficiency, post-
bleeding reticulocytosis, initial response to iron treatment, 
alcohol intake or mild myelodysplasia. 
When anemia in CRC cannot be explained by IDA or 
FID + ID, it is important to consider other causes that 
would demand specific treatment. In these cases, further 
testing should include B12, lactate dehydrogenase, and 
serum creatinine in order to exclude other nutritional defi-
ciencies, hemolysis or renal disease[29-33]. If  malabsorption 
or severe malnutrition, a red cell folate may also be useful.
in CRC tissue. Hepcidin immunoreactivity was found in 
34% specimens from patients with CRC and was cor-
related with ferroportin inhibition. Urinary hepcidin was 
positively associated with increasing CRC tumor stage, 
but not with anemia. This suggests that CRC hepcidin, 
rather than hepatic hepcidin, is involved in a proportion 
of  cases of  CRC-associated anemia more likely to be IDA 
(or FID + ID) rather than FID and will respond to iv iron 
rather than oral iron[25].
DIAGNOSIS
The prevalence of  gastrointestinal (GI) pathology among 
IDA patients varies from 43% to 86%, the most com-
mon being benign erosive lesions in the upper GI tract, 
accounting for 39%-57% of  upper GI with CRC, ac-
counting for 42%-69% of  lower GI lesions[26]. IDA is a 
known harbinger of  CRC mandating evaluation. When-
ever clinically feasible, at four weeks prior to elective 
CRC surgery an anemia evaluation including standard 
iron parameters should be performed. If  indicated, ap-
propriate intervention should be implemented, as they 
decreases perioperative morbidity[27,28]. Laboratory screen-
ing for anemia in CRC should include, at least, a CBC, 
reticulocytes and assessment of  iron parameters (Fe, 
TSAT, ferritin) (Table 1), and C-reactive protein (CRP), 
which is useful in determining the presence or absence 
of  inflammation[29-33]. The presence of  anemia should be 
considered when the Hb level is < 13 g/dL for men and 
< 12 g/dL for women. However, a normal Hb level does 
not exclude ID, as blood loss is nearly always the cause 
and a significant amount must occur before iron deficient 
erythropoiesis begins. In non-anemic ID patients, the 
symptom of  chronic fatigue is non-specific and a labora-
tory finding of  a low serum ferritin provides an indirect 
Laboratory test Normal values
Conventional units Conversion factor2 SI units
Iron status in the body 
   Serum iron 50-180 g/dL  × 0.179 9-32 mol/L
   Transferrin 200-360 mg/dL × 0.01 2-3.6 g/L
Transferrin saturation 20%-50%
   Ft 30-300 ng/mL  × 2.247 65-670 pmol/L
   sTfR1 0.76-1.76 mg/L 6.4-25.7 nmol/L
   sTfR/log Ft < 1
Iron deficient red cell production
   Hb 12-16 g/dL ♀     × 0.62063 7.5-10 mmol/L
13-17 g/dL ♂ 8-10.5 mmol/L
   Mean corpuscular volume 80-100 fL
   Red cell distribution width 11-15
   Mean corpuscular Hb 28-35 pg
   Hypochromic red cells < 5%
   Reticulocyte Hb content 28-35 pg
1Normal values may differ depending on the assay used; 2To convert the concentrations values in conven-
tional unit into SI units multiply figures by the conversion factor; 3In fact, although widely used, this factor 
allows for the calculation the molar concentration of hemoglobin subunits. Thus, the molar concentration 
of hemoglobin (Mw 64 kDa) is 4-fold times lower (2-3 mmol/L). Ft: Ferritin; sTfR: Soluble transferrin re-
ceptors; Hb: Hemoglobin; sTfR/log Ft: Ratio of sTfR to serum Ft.
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TREATMENT OPTIONS
Allogeneic blood transfusion
After CRC surgery, perioperative blood loss and post-
operative blunted erythropoiesis, due to surgery-induced 
inflammation, may lead to severe postoperative anemia, 
especially in those presenting with low preoperative Hb. 
In this context, ABT continues to be the most frequently 
used treatment for acute intra- and post-operative ane-
mia, although its quick and effective increase in Hb levels 
is transitory, and is associated with poorer outcomes. 
Subsequently, ABT should be restricted to those with 
severe anemia, poor physiological reserve and/or acute 
symptoms requiring immediate correction.
Perioperative ABT is associated with increased rates 
of  cancer recurrence[36,37]. In a meta-analysis, 23 out of  
36 studies on 12127 patients showed a detrimental effect 
of  ABT. After ABT a higher rate of  tumor recurrence 
compared to those not transfused with a clustered OR 
of  1.42[38] was observed. In a more recent meta-analysis, 
ABT has been shown to increase all-cause mortality (OR 
= 1.72), cancer-related mortality (OR = 1.71) and mor-
bidity, such as wound infection (OR = 3.27), after CRC 
resection[39]. Subsequently, many medical scientific societ-
ies recommend a restrictive approach for perioperative 
ABT, in which the level of  Hb below which an ABT unit 
is transfused (i.e., the “transfusion trigger”) should be 
intimately related to the ability to tolerate normovolemic 
anemia relative to available cardiopulmonary reserve[40,41]. 
In non-bleeding, euvolemic anemic patients, ABT is rec-
ommended to maintain Hb levels between 7 and 9 g/dL 
(8-10 g/dL for those with cardiac and/or central nervous 
system dysfunction)[40,41].
Malignancy and surgery are known prothrombotic 
stimuli, and perioperative ABT may further increase the 
risk for venous thromboembolism (VTE). The analysis 
of  two databases of  almost 3000 CRC resections dem-
onstrated that intraoperative ABT was a significant risk 
factor for the development of  VTE, increasing with in-
creased number of  units transfused[42,43]. In this analysis 
the risk for VTE in women was statistically greater than 
in men. Preoperative hematocrit did not enter the multi-
variable model as an independent predictor of  VTE, or 
did open versus laparoscopic resection or wound class[43]. 
The diagnosis of  almost one third of  postoperative VTE 
occurred after discharge[44]. Subsequently, the Enhanced 
Recovery after Surgery (ERAS) program recommends 
extended postoperative prophylaxis with low-molecular 
weight heparin for 28 d in CRC patients[45].
In summary, available data strongly recommend mini-
mizing ABT in CRC surgery, using restrictive transfusion 
policies and implementing ABT alternatives, with empha-
sis on thromboprophylaxis after discharge.
Pharmacologic treatment
Objectives: The goal of  preoperative anemia therapy 
should be normalization of  the Hb levels, in accordance 
with World Health Organization criteria. However, as 
CRC resections are procedures with a moderate-to-high 
blood loss, it would be desirable to achieve a Hb of  13 
g/dL for both genders to minimize the risk for transfu-
sion. Similarly, postoperative anemia treatment should 
be aimed to attain Hb levels which avoid or reduce the 
exposure to ABT, followed by its correction in the short-
est possible period, to favourably influence sensitivity to 
adjuvant treatments, facilitate the functional recovery and 
improve quality of  life.
Iron replacement: In CRC, ID with or without anemia 
should be corrected pre-operatively by iv iron, with or 
without an erythropoiesis stimulating agent (ESA), pref-
erably two to four weeks prior the scheduled procedure. 
While at least four studies explored the efficacy of  pre-
operative oral iron[46-49] (Table 2), the results are routinely 
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Hb <13 g/dL 
Evaluate medical history, clinical status, co-morbidities and medication
TSAT < 20% TSAT > 20%
Ferritin < 30 mg/L




> 100 mg/L Vitamin B12 and Folate
IDA1 FID + ID3 FID2 Normal Low + MCV > 100 fL
AUC4 Others5 Macrocytic anemia4
Figure 3  An algorithm for anemia diagnosis. Modified from Muñoz et al[20]. ACD: Anemia of chronic disease; AUC: Anemia of unknown cause; CHr: Reticulocyte 
hemoglobin; CKD: Chronic kidney disease; CRP: C-reactive protein; Ft: Ferritin; Hb: Hemoglobin; ID: iron deficiency; IDA: Iron deficiency anemia; MCH: Mean corpus-
cular hemoglobin; MCV: Mean corpuscular volume; sTfR: Serum transferrin receptor; TSAT: Transferrin saturation; FID: Functional iron deficiency.
1Rule out other causes
2Reticulocytes, creatinin, CRP
3sTfR/log Ft > 2, hypocromic RBC, CHr
4Refer to the hematologist
5CKD, haemolysis, acute blood loss, etc .
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inferior to those with the iv iron route[50].
Okuyama et al[46] compared preoperative Hb levels 
and transfusion requirements of  anemic patients (Hb 
≤ 10 g/dL), 32 who received oral iron supplementa-
tion (sodium ferrous citrate, 200 mg/d) for at least 2 wk 
preoperatively with those of  84 who did not. While iron 
supplementation resulted in higher Hb levels immedi-
ately before surgery (+1.2 g/dL; P < 0.05), and fewer 
required intraoperative ABT (9.4% vs 27.4%, P < 0.05), 
there were no significant differences in postoperative Hb 
levels or ABT volumes between the two groups. Lidder 
et al[47] conducted a randomized controlled trial (RCT) of  
oral ferrous sulphate (200 mg TDS) for a mean of  14 d 
pre-operatively (12-56 d) vs no iron therapy in patients 
with IDA or ID scheduled for CRC surgery. Oral iron 
was found to prevent Hb decrease from recruitment to 
admission, and to reduce ABT (25% vs 59%, for iron and 
control, respectively; P = 0.031), although these differ-
ences were not statistically significant for patients with 
IDA. 
In a series of  103 patients receiving oral ferrous sul-
phate (200 mg TDS) for a median of  39 d pre-operatively 
(interquartile range = 7-63 d) and no preoperative ABT, 
Quinn et al[48] observed that: (1) fifty-eight (56.3%) pa-
tients who were anemic at presentation had a mean incre-
ment in Hb of  1.7 g/dL (P < 0.001); (2) those with right-
sided tumors (lower mean Hb at presentation) responded 
more often to oral iron than those with left-sided tumors 
(P < 0.017); (3) increase in Hb was unrelated to tumor 
stage, but was greater when iron was administered for 
more than 14 days; and (4) ABT rate for all curative re-
sections was 0.69 units/patient (compared to 1.69 units/
patient using an historical cohort). 
Several iv iron formulations are currently available 
(Table 3). iv iron therapy, with or without ESAs, as a safe 
and efficacious tool for treating anemia and reducing 
transfusion requirements in surgical and medical patients, 
has been extensively reviewed[51-54]. Randomized clinical 
trials have shown superior efficacy of  iv iron over oral or 
no iron in reducing ABT, increasing Hb, and improving 
quality of  life in ESA-treated anemic cancer patients[53,55]. 
In contrast, studies examining iv iron as sole anemia 
treatment in cancer patients are only just starting to 
emerge, and the role of  iv iron for correcting periopera-
tive anemia is frequently overlooked in the surgical care 
of  cancer patients[56-60]. 
Two case series illustrates the potential benefits of  
pre- or peri-operative iron supplementation in CRC re-
sections. Campos et al[61] studied 43 CRC patients who 
received preoperative oral iron (100 mg/d) if  Hb > 14 
g/dL and iron deficiency was present; iron sucrose (200 
mg/wk) if  Hb 10-14 g/dL; or iron sucrose (200 mg twice 
a week) if  Hb < 10 g/dL, during weeks 3-4. Seventeen 
received postoperative iron sucrose (200 mg on days 0, 
2, and 4). A retrospective series not receiving iron was 
used as a control (n = 66). Despite a lower baseline Hb 
(12.3 g/dL vs 11.5 g/dL; P < 0.05), iron therapy reduced 
the transfusion index (4.0 unit/patient vs 1.3 unit/patient; 
P < 0.05) and the percentage of  patients who received 
preoperative ABT (33% vs 9%; P < 0.05), but not the 
percentage of  patients administered perioperative ABT 
(48% vs 35%; P = 0.161). However, the treatment was 
ineffective in patients with a high transfusion index (> 5 
units/patient).
Díaz Espallardo et al[62] analyzed data from 437 CRC 
surgeries from 2005-2009. Patients presenting with Hb 
Table 2  Characteristics of the clinical studies examining the role of preoperative iron replacement in colorectal cancer included in 
this review
Study Study design Patients Baseline Hb (g/dL) Iron compound dose (mg) Duration (wk) Hb (g/dL) ABT (% or U/pt)
Oral iron
   Okuyama et al[46] OBS Iron: 32   8.1 ± 1.4 Ferrous citrate ≥ 2  2.0   9.4%
No iron: 84   8.0 ± 1.6 (200 mg/d)  0.9 27.4%
   Lidder et al[47] RCT Iron: 23 13.4 ± 1.9 FS 2-8 -0.3 26.0%
No iron: 22 12.4 ± 2.1 (200 mg TDS) -0.6 59.0%
   Quinn et al[48] OBS Iron: 103 12 (10-14) FS 1-9 0.69 U/pt
No iron: 167 NS (200 mg TDS) 1.69 U/pt
   Ferrari et al[49] RCT FB: 12 11.6 ± 1.6 FB 8 1 (2) mo NS
(28-14 mg/d) 0.8 (1.4)
FS: 12 11.3 ± 1.2 FS 0.7 (1.4)
(105 mg/d)
Intravenous iron
   Edwards et al[57] RCT Iron: 34 13.7 ± 0.5 IS 2 -0.2 14.7%
Placebo: 26 13.4 ± 0.4 (2 × 300 mg) -0.5 19.2%
   Bisbe et al[64] OBS IS: 30 10.1 ± 1.2 IS 2-6  0.9   7.0%
(100-200 mg, 6 ± 3 doses)
FCM: 15   9.2 ± 1.0 FCM  2.5 40.0%
(500-1000 mg, 3 ± 1 doses)
   Todman et al[68] Case series Iron: 22 < 12 Iron isomaltoside-1000 2-6 0.7, 1-2 w NS
(20 mg/kg bw) 1.4, 3-4 w
3.1, 6-8 w
RCT: Randomized controlled trial; OBS: Observational cohort study; Hb: Increment from baseline; ABT: Allogeneic blood transfusion; FB: Ferrous bisglici-
nate; FS: Ferrous sulphate; IS: Iron sucrose; FCM: Ferric carboxymaltose.
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<13 g/dL and/or abnormal iron parameters, (group A, n 
= 242) received preoperative iron supplementation (178 
received a mean of  867 mg iv iron sucrose, and 64 oral 
iron), whereas those presenting with Hb ≥ 13 g/dL and 
normal iron status, received no treatment (group B, n = 
195). From diagnosis to surgery, Hb increased by 0.6 g/
dL in group A, while it decreased by 0.8 g/dL in Group 
B (P < 0.05). From diagnosis to discharge, Hb decreased 
by 0.4 g/dL in group A, and by 2.5 g/dL in group B (P 
< 0.05). This tendency to progressive anemia observed 
in both groups may be secondary to the effects of  CRC 
on erythropoiesis, chemo-radiotherapy treatment, and 
blood loss due to the tumor and later surgery. However, 
the differences between groups strongly suggest that iron 
therapy prevented patients from group A from reaching 
low Hb levels. The overall ABT rate was 8.6% (32/244, 
13.1% vs 6/195, 3.1%; P = NS) and no differences in 
complications were observed. 
In contrast, in a retrospective paired case-control 
study, Titos-Arcos et al[63] observed that postoperative 
administration of  iv iron sucrose (592 ± 445 mg) did not 
decrease ABT rates (28.8% vs 30.8%, for case and con-
trol, respectively). In addition, for patients not receiving 
ABT, there were no differences in Hb concentration de-
crease between the first postoperative day and discharge 
(0.88 g/dL vs 0.82 g/dL, for case and control).
Higher vs lower dose intravenous iron administration: 
Bisbe et al[64] compared clinical and laboratory data of  15 
anemic CRC receiving preoperative ferric carboxymaltose 
(FCM, 500-1000 mg/session; 3 ± 1 sessions) to those 
from a previous series of  30 CRC receiving preoperative 
iron sucrose (100-200 mg/session; 6 ± 1 sessions). Even 
though those in the FCM group had lower baseline Hb 
levels (9.2 g/dL vs 10.1 g/dL; P < 0.05), those from the 
FCM group showed a higher post-treatment Hb incre-
ment (+2.5 g/dL vs +0.9 g/dL; P < 0.05), and received 
fewer perioperative ABT (7% vs 40%; P > 0.05). While 
the total amount of  iv iron infused in the FCM group was 
higher (1550 mg vs 1140 mg; P < 0.05) most clinical trials 
suggest 1000 mg is an adequate replacement dose[65-67]. 
Todman et al[68] administered a single dose iron infusion 
(Iron isomaltoside-1000, 20 mg/kg body weight) to 22 
major cancer surgery patients with IDA either 2-6 wk be-
fore surgery, or post-operatively. Hemoglobin levels were 
monitored for up to 8 wk after infusion, or up to next 
blood transfusion, whichever was earlier. Mean Hb rise at 
1-2 wk was 0.7 g/dL, 1.4 g/dL at 3-4 wk and 3.1g/dL at 
6-8 wk, and no serious adverse effects were noted (Table 
2).
This apparent superiority of  “higher dose” over 
“lower dose” iv iron supplementation in improving eryth-
ropoiesis has been also reported for inflammatory bowel 
disease[69], and several factors might have account for the 
observed differences. Firstly, the “extra” amount of  iron 
administered to the FCM group could have compensated 
for the ongoing blood loss from recruitment to surgery. 
Secondly, macrophage iron loading may also inhibit pro-
inflammatory immune effector pathways[18,70]. Lastly, in 
iron balance, high hepcidin also reduces IL-6 production 
by macrophages, thus limiting the potential damage of  
an excessive inflammatory response[71]. As ID is highly 
prevalent among CRC, it is possible that rapid repletion 
with higher dose of  iv iron can contribute in restoring an 
adequate immune response, improving the erythropoietic 
response.
As summarized in Table 2, initial results with preop-
erative oral or iv iron replacement therapy in CRC have 
been mixed, highlighting the need for large randomized 
controlled trials in preoperatively anemic patients.
Safety of  intravenous iron: Although no serious ad-
Table 3  Some characteristics of the different intravenous iron formulations












Brand name Ferrlecit® Venofer® Dexferrum® Cosmofer® Ferinject® Monofer® Rienso®
INFeD® Injectafer® FeraHeme®


















Molecular weight (kDa) 289-440 30-60 265 165 150 150 750
Plasma half-life (h) 1   6   60   20   16   20   15
Direct iron donation to 
transferrin (% injected 
dose)
5-6 4-5 1-2 1-2 1-2 < 1 < 1
Test dose required1 No Yes/No Yes Yes No No No
Iron content (mg/mL) 12.5 20   50   50   50 100   30
Maximal single dose (mg) 125 200-300 20 mg/kg 20 mg/kg2 20 mg/kg (max 
1000 mg in one 
infusion)
20 mg/kg   5103
Premedication No No TDI only No No No No
Life-threatening ADE 
(× 106 doses)
0.9 0.6 11.3 3.3 ?? ?? ??
1A test dose is no longer recommended by the European Medicines Agency (2013); 2Low molecular weight iron dextran can be safely administered at doses 
of 1000 mg over 1 h[101]; 3Preliminary data indicate that Ferumoxytol may be administered at doses of 1020 mg over 15 min[102].
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verse drug events (SAEs) have been reported in the stud-
ies reviewed, both the numbers and follow-up time were 
not large enough to draw definitive conclusions regarding 
the safety of  iv iron agents in this clinical setting. In all 
published evidence extant, including millions of  dialysis 
patients, no long term toxicity has been reported over the 
last two decades[72].
As of  June 28th 2013, the European Medicines 
Agency’s Committee for Medicinal Products for Human 
Use (CHMP) concluded that the benefits of  iv exceed 
their risks, provided that adequate measures are taken to 
minimize the risk of  allergic reactions. Data on the risk 
of  hypersensitivity comes mainly from post-marketing 
spontaneous reports and the total number of  life-
threatening and fatal events reported is low, and cannot 
be used to detect any differences in the safety profile of  
the different iron formulations available in Europe (high 
molecular weight iron dextran and ferumoxytol were not 
included). The CHMP has issued recommendations for 
health care professionals which include: (1) intravenous 
iron medicines should only be administered when staff  
trained to evaluate and manage anaphylactic and ana-
phylactoid reactions are immediately available as well as 
resuscitation facilities; (2) a test dose is no longer recom-
mended, as there are data indicating that allergic reac-
tions may still occur in patients who have not reacted to 
a test dose; (3) patients should be closely observed for 
signs and symptoms of  hypersensitivity reactions during 
and for at least 30 min following each injection of  an iv 
iron medicine; and (4) intravenous iron-containing prod-
ucts are contraindicated in patients with hypersensitivity 
to a specific active substance or excipients, or other par-
enteral iron products.
Early formulations of  high molecular weight iron dex-
tran were associated with rare occurrences of  anaphylaxis 
and even death. The newer formulations, LMW ID, ferric 
gluconate, iron sucrose, ferumoxytol, iron isomaltoside 
and ferric carboxymaltose are much safer with SAEs van-
ishingly rare. None the less minor infusion reactions still 
occur and are often misinterpreted as SAEs[53]. Premedi-
cation with antihistamines has been reported to cause 
the majority of  perceived reactions to iv iron in one large 
cohort[73]. Antihistamines can cause somnolence, diapho-
resis, hypotension and tachycardia ostensibly attributed 
to the administered iron. Tryptase a marker of  mast cell 
degranulation, levels are virtually always normal and sub-
sequently the use of  premedication with antihistamines 
should be proscribed. In contradistinction, all of  the 
formulations can be associated with acute chest and back 
tightness, without accompanying hypotension, tachypnea, 
tachycardia, wheezing, stridor or periorbital edema[51,74]. 
These infrequent reactions abate without therapy and 
rarely recur with rechallenge. The reactions are more fre-
quent in those with allergic diatheses[65]. It is important 
not to overreact in the event of  these minor AEs. A few 
patients will experience self-limited arthralgias and my-
algias the day after iron infusions. These reactions abate 
without therapy and never leave residua. Non-steroidal 
anti-inflammatory drugs may shorten their duration. 
When these tenets are adhered to the administration of  iv 
iron is safe and much safer than most physicians realize.
Erythropoiesis stimulating agents: The role of  iv iron 
for CRC-related anemia remains unclear. It is possible that 
the effectiveness of  perioperative iron treatment could be 
enhanced by concomitant ESA administration, although 
in Europe this is an off-label use of  these growth factors. 
Pooled data from six trials (621 patients) showed that 
perioperative treatment with recombinant human eryth-
ropoietin did not reduced ABT (33% vs 37%; OR = 0.89; 
P = 0.206) in GI cancer surgery[75-80] (Table 4). Norager 
et al[80] explored the effect of  perioperative ESA adminis-
tration in CRC surgery (Table 4). No significant benefits 
were found for postoperative fatigue, quality of  life, 
muscle strength or ABT use, but improved work capacity 
and early restoration of  postoperative Hb concentrations 
to preoperative levels were observed. The treatment was 
uniformly well tolerated. Unfortunately, the impact of  
ESA therapy on anemic CRC patients was not analyzed 
separately. However, a reduction of  both the percentage 
of  transfused patients and the number of  transfused units 
was only observed for those receiving ESAs plus iv iron. 
Additionally, the use of  iv iron allowed for a significant 
reduction in the total dose of  ESAs (Table 4). 
Safety of  erythropoiesis stimulating agents: ESA 
prevent transfusions among chemotherapy-associated 
anemia patients. An ESA-associated increase in mortal-
ity and/or disease progression has also been reported in 
eight controlled studies conducted in CIA however in 
each of  these the ESA use was off-label. Another meta-
analysis of  60 studies (15323 patients) showed no signifi-
cant effect of  ESAs on survival or disease progression, 
but increased the risk for venous-thromboembolic events 
(44 studies: OR = 1.48; 95%CI: 1.28-1.72)[81]. However, 
venous-thromboembolic events in cancer patients re-
ceiving ESAs for chemotherapy induced anemia may be 
linked to thrombocytosis due to ESA induced iron re-
stricted erythropoiesis, which can be reversed by adminis-
tration of  iv iron[82,83]. Nevertheless, product labels advise 
against administering ESAs with potentially curative 
chemotherapy (United States) or to conduct risk-benefit 
assessments (Europe/Canada) and, since 2007, fewer 
chemotherapy-associated anemia patients in the United 
States and Europe receive ESAs[84-87]. 
In CRC surgery, a recent systematic review and meta-
analysis of  4 RCTs also found insufficient evidence to 
support the use of  ESAs in the preoperative and post-
operative period for improving anemia and decreasing 
ABT. There were no significant differences in post-
operative mortality or thrombotic events between groups, 
but no included study evaluated recurrences, survival, or 
quality of  life[88]. 
Vitamin replacement: Deficiencies of  vitamin B12, 
with or without anemia, should be appropriately man-
aged. The intramuscular route is preferred (hydroxyl-
cobalamin, 1 mg/wk, 4-6 wk), except for vegans (oral 
route) or anticoagulated patients (iv route).
P- Reviewers  Bener A    S- Editor  Wen LL    L- Editor  Cant MR    E- Editor  Ma S
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Adjuvant measures
Nutritional support: Poor pre-operative nutritional 
status has been linked consistently to an increase in post-
operative complications and poorer surgical outcome. 
Patients should be screened for nutritional status and, if  
deemed to be at risk of  under-nutrition, given active nu-
tritional support[45]. 
Meta-analyses were undertaken on trials evaluating 
different preoperative nutritional interventions. Benefits 
on post-operative complications and length of  hospital 
stay of  preoperative immune enhancing nutrition or par-
enteral nutrition may not be generalized or are not appli-
cable to current clinical practice, whereas trials evaluating 
enteral or standard oral supplements were inconclusive[89]. 
Therefore, except for the severely malnourished, whether 
or not nutritional intervention should be initiated earlier 
in the preoperative period remains unclear.
In contrast, post-operative management in gastroin-
testinal surgery is becoming well established with ERAS 
protocols starting 24 h prior to surgery with carbohydrate 
loading, minimization of  preoperative fasting and early 
oral or enteral feeding given to patients the first day fol-
lowing surgery (with oral nutritional supplements if  nec-
essary). ERAS is aimed to reduce surgical stress, insulin 
resistance, unnecessary protein losses and postoperative 
complications. In comparison with traditional care, ERAS 
programs were associated with significantly decreased 
length of  hospital stay and total and general complica-
tions, without affecting readmission rates, surgical com-
plications, and mortality[90].
Preventing perioperative hypothermia: Perioperative 
maintenance of  normothermia with a suitable warming 
device and warmed iv fluids to keep body temperature > 
36 ℃ decreased intraoperative blood loss and postopera-
tive shivering, and it has been associated with lower rates 
of  postoperative infection and better pain scores[45,91-94].
Restrictive fluid replacement (fluid balance): Hypo-
volemia can lead to hypoperfusion of  vital organs and the 
bowel, which can lead to complications, and appropriated 
fluid reposition with balanced crystalloid solutions should 
be performed. However, administering too much may re-
sult in bowel edema, increased interstitial lung water, and 
dilution anemia which can also lead to complications[95]. 
The evidence suggests that patients being in a state of  
‘‘fluid balance’’ (goal-directed fluid replacement) fared 
better than those with ‘‘fluid imbalance’’[96-99]. Postopera-
tive iv fluids should be aimed to maintain normovolemia 
and avoid fluid excess. The enteral route should be used 
in preference and the drip taken down at the earliest op-
portunity (preferably no later than the morning after sur-
gery)[45].
Perioperative supplemental oxygen: Although the role 
of  perioperative supplemental oxygen in anemia tolerance 
has not been properly investigated, it has been proposed 
to decrease the incidence of  surgical site infection in 
CRC surgery. This positive effect was not confirmed by a 
recent meta-analysis of  5 RCTs[100]. However, supplemen-
tal oxygen appears to confer a mortality benefit, a previ-
ously unreported finding that needs to be confirmed.
Table 4  Effects of perioperative administration of erythropoietin and iron on transfusion requirements in patients undergoing 
elective colorectal cancer resection
Study +ESA Placebo Iron ESA
n ABT, n  (%) n ABT, n  (%) (route, type, dose, d) (type, total dose, route, day)
Braga et al[75]   10      1 (10)1   10     5 (50) iv iron gluconate, 125 mg/d, 4 d Epoetin alfa, 
500 IU/kg, SC
(from day -12 to day +8)
Kettelhack et al[76]   48   16 (33)   54   15 (28) Oral, NS, 5-10 d preOP Epoetin beta, 
iv, NS, 40 mg, 1 d postOP 3000-4500 IU/kg, SC
(from day -10 to day +4)
Qvist et al[77]   38    13 (34)2   43   23 (53) Oral, NS, Epoetin alfa,
200 mg/d, 4 d 1350 IU/kg, SC
(from day -4 to day +7)
Kosmadakis et al[78]   31      9 (29)1   32   19 (59) iv iron sucrose, Epoetin alfa,
100 mg/d, 14 d 4200 IU/kg, SC
(from day -7 to day +7)
Christodoulakis et al[79] 69 (a)   34 (49)   68   35 (51) Oral, NS, Epoetin alfa,
67 (b)    27 (40)2 200 mg/d, 10 d 1800 IU/kg, SC (a)
3600 IU/kg, SC (b)
(from day -10 to day +1)
Norager et al[80]   75   10 (13)   76     9 (12) Oral, NS, Darbepoetin alfa,
200 mg/d, 7d 750-1500 g, SC
(from day -10 to day +25)
Overall 338 110 (33) 283 106 (37) OR = 0.89 (95%CI: 0.58-1.12; P = 0.206)
1Reduction in both percentage of transfused patients and number of transfused units; 2Reduction in the number of transfused units only. ABT: Allogeneic 
blood transfusion; ESA: Erythropoiesis stimulating agent; NS: Not stated; preOP: Preoperative; postOP: Postoperative; SC: Subcutaneous.
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FROM LITERATURE TO BED-SIDE: 
A PRAGMATIC APPROACH TO CRC 
ASSOCIATED ANEMIA
“Time is gold for anemic patients waiting for CRC 
resection”
Early and aggressive treatment of  anemia in CRC enables 
optimization of  preoperative Hb, thus transforming a 
high transfusion risk to a low transfusion risk, which im-
proves outcomes. Therefore, we developed a pragmatic, 
easy-to-follow protocol for diagnosis and treatment of  
preoperative CRC associated anemia, which is based 
upon the following considerations.
Diagnosis
Basic laboratory screening for anemia in CRC should 
comprise Hb, full blood counts (including reticulocytes), 
and assessments of  body iron store (serum ferritin), iron 
availability (TSAT) and level of  inflammation (CRP). 
Should anemia not be explained by initial work-up, fur-
ther testing could comprise vitamin B12 and folic acid, 
haptoglobin, lactate dehydrogenase, and serum creatinine 
if  other laboratory tests indicate their usefulness (Figure 
3). These are low-cost, widely available tests which allow 
for correctly classifying most cases of  CRC-associated 
anemia.
Treatment 
Iron therapy: As IDA and FID + ID are the most fre-
quent types of  anemia in CRC, iron supplementation is of  
paramount importance and can be accomplished by fol-
lowing the algorithm depicted in Figure 4. The estimated 
total iron deficiency take into account the amount of  iron 
needed to restore a Hb level of  13 g/dL and to replenish 
iron stores, as well as estimated iron loss due to ongoing 
chronic bleeding and perioperative blood loss.
Erythropoiesis stimulating agents: Until more safety 
data in CRC are available, ESAs should be only used in 
the approved indications and following the recommenda-
tions of  international guidelines. 
Restrictive transfusion protocol: In most surgical CRC 
Hb ≥ 13 g/dL:
Ferritin < 30 ng/mL + CRP < 5 mg/L
Ferritin < 100 ng/mL + CRP > 5 mg/L,
TID: 500-600 mg
Iron deficiency without anemia
Oral iron
(100 mg/d)
IV iron to cover TID
Iron sucrose (3 doses) 
200 mg/s
FCM, MNF or LMWID 
(1 dose)
500-600 mg (≤ 20 mg/kg)
Hb ≥ 10 g/dL - <13 g/dL:
Ferritin < 100 ng/mL
Transferrin saturation < 20%
TID: 700-1000 mg 
Moderate iron deficiency anemia
Oral iron
(100 mg/d)
IV iron to cover TID
Iron sucrose (4-5 doses) 
200 mg/s (max. 600 mg/wk)
LMWID or MNF (1 dose)
max. 2000 mg/s (≤ 20 mg/kg)
2 wk
Hb increase ≥ 1 g/dL
Continue therapy
FCM (1 dose)
max. 1000 mg/s (≤ 20 mg/kg)
Hb < 10 g/dL:
Ferritin < 100 ng/mL
Transferrin saturation < 20%
TID > 1000 mg 
Severe iron deficiency anemia
FCM (2 doses)
max. 1000 mg/s (≤ 20 mg/kg)
Iron sucrose (> 5 doses) 
200 mg/s (max. 600 mg/wk)
LMWID or MNF 
(1- 2 doses)
max. 2000 mg/s (≤ 20 mg/kg)
Surgery
Follow up
Figure 4  An algorithm for iron replacement. Modified from Muñoz et al[31]. FCM: Ferric caboxymaltose; Hb: Hemoglobin; LMWID: Low molecular weight iron dex-
tran; MNF: Iron isomaltoside-1000; s: Session; TID: Total iron deficiency; CRP: C-reactive protein. 
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patients, ABT could be considered for maintaining Hb 
concentrations between 7 and 9 g/dL; for those with 
cardiac and/or central nervous system dysfunction, ABT 
could be considered for patients with symptoms or a Hb 
level of  8 g/dL or less, and ABT given for maintaining 
Hb concentrations between 8 and 10 g/dL[40,41] Carson 
2011. However, whenever possible, avoidance of  ABT is 
preferable.
Adjuvant therapies: All of  above mentioned measures 
aimed to decrease blood loss, hemodilution and post-
operative hyper-catabolism should also be implanted, as 
they may contribute to reduce the severity of  and to has-
ten the recovery from postoperative anemia. 
Follow-up
Patients should be followed-up for documenting the re-
covery from postoperative anemia, especially if  adjuvant 
chemotherapy and/or radiotherapy were administered.
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